In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.
In vitro activities of ABT-492, ciprofloxacin, levofloxacin, trovafloxacin, moxifloxacin, gatifloxacin, and gemifloxacin were compared. ABT-492 was more potent against quinolone-susceptible and -resistant gram-positive organisms, had activity similar to that of ciprofloxacin against certain members of the family Enterobacteriaceae, and had comparable activity against quinolone-susceptible, nonfermentative, gram-negative organisms. Bactericidal activity of ABT-492 was also evaluated.
Almer
Laurel S
LS
Infectious Diseases Research, R47T, AP52N, Abbott Laboratories, Abbott Park, IL 60064-3537, USA. laurel.s.almer@abbott.com
Hoffrage
Jennifer B
JB
Keller
Erika L
EL
Flamm
Robert K
RK
Shortridge
Virginia D
VD
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000378:metabolism; D002352:Carrier Proteins / Q000378:metabolism; D024841:Fluoroquinolones / Q000494:pharmacology; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000235:genetics; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000235:genetics; D006602:Hexosyltransferases / Q000378:metabolism; D007700:Kinetics; D008826:Microbial Sensitivity Tests; D002267:Muramoylpentapeptide Carboxypeptidase / Q000378:metabolism; D010403:Penicillin Resistance; D046915:Penicillin-Binding Proteins; D010458:Peptidyl Transferases / Q000378:metabolism; D015363:Quinolones / Q000494:pharmacology*; D020713:Vancomycin Resistance
D000890:Anti-Infective Agents; D001426:Bacterial Proteins; D002352:Carrier Proteins; D024841:Fluoroquinolones; D046915:Penicillin-Binding Proteins; D015363:Quinolones; C477891:delafloxacin; D010458:Peptidyl Transferases; D006602:Hexosyltransferases; D002267:Muramoylpentapeptide Carboxypeptidase